Neuron News

Psilocybin for Fragile X Syndrome
Approved by Health Canada

Magic mushrooms will be going into the first ever Phase 2a clinical trial for use in fragile X syndrome, a cause of autism spectrum disorder.

Human testing on adults with fragile X will be done for the first time. It is hoped that the testing will show behavioral and cognitive symptom improvements. In addition, there will be psilocybin based treatments tested for neuroinflammatory disorders.

BRAINWeek 2023

September 7-9
Practical education for specialists andfrontline practitioners treating CNS disorders
UPCOMING EVENTS

Subscribe

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.